Orphan diseases Congress

Dr Geoffrey Guy is the founder of GW Pharmaceuticals and has served as Chairman since 1998. Dr Guy has over 30 years of experience in medical research and global drug development, most recently as Chairman and Chief Executive of Ethical Holdings plc (now Amarin Corporation plc, or Amarin), which he founded in 1985. He also founded Phytopharm plc in 1989, of which he was Chairman until 1997. Dr Guy has been the physician in charge of over 200 clinical studies including first dose in man, pharmacokinetics, pharmacodynamics, dose-ranging, controlled clinical trials and large scale multi-centred studies and clinical surveys. He is also an author on numerous scientific publications and has contributed to six books. He has received various awards during his career.

Dr Anthony Hall (Tony) joined the pharmaceutical industry in 1994 before starting his own company in 2001, providing drug development consultancy and other services to the biopharmaceutical industry. Since 2010, Tony has focused exclusively on the orphan drugs and rare diseases sector. Tony is Co-Founder of Findacure, to which he devotes part of his time, also providing pro bono advice to the AKU society and other patient groups. The rest of his time he works as a consultant, providing advice and guidance on the development of orphan drugs to the biopharmaceutical industry. He is an elected member of the IRDiRC Working Group on Orphan drug-development and regulatory processes.

Hans Schikan is CEO of Prosensa (NASDAQ: RNA), an innovative Dutch biopharmaceutical company focusing on the discovery, development and commercialization of novel treatments for rare diseases like Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease, using its RNA modulation platform. Before joining Prosensa, Hans worked at Genzyme for five years in various executive roles. Prior to Genzyme, he spent 17 years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Next to his role at Prosensa, Hans is currently Executive Board Member of the Dutch Top Institute Pharma, Non-executive Director of Sobi (Swedish Orphan Biovitrum) and Member of the Core Team of the Dutch Top Sector Life Sciences & Health, Member of the Biotechnology Industry Organization’s Emerging Companies Section Governing Board.

Ann-Teresa is the founder and Managing Editor of the Orphan Druganaut Blog. The Orphan Druganaut Blog provides competitive intelligence, news, and internet buzz on global rare diseases and orphan...

You might also like
Rania Al Shami of Ergomed at World Orphan Drug Congress
Rania Al Shami of Ergomed at World Orphan Drug Congress ...
Orphan Drug Congress April 2013: Part 1, Approaches to
Orphan Drug Congress April 2013: Part 1, Approaches to ...
Research of Rare and Orphan Diseases: Re(ACT). International Congress on Research of Rare and Orphan Diseases, Basel, February/March 2012. Special Topic Issue: 'Molecular Syndromology 2012, Vol. 3, No. 5' (Paperback) - Common
Book (S Karger Ag)

Popular Q&A

avatar
What does the FDA do? a topic, disease, or research study that the FDA is involved with and describe it?

what does the FDA do? a topic, disease, or research study that the FDA is involved with and describe it’s involvement?

The FDA takes possible cures to diseases and slows down the process of making it legal to buy and use to fix your ailments. They do this because of all the donated money to help finding a cure (for example cancer, or aids) If someone were to find a cure for a disease then they would stop getting the donation money. Theres more money to be made in finding cures rather then creating a cure. FACT

Related Posts